

# HOUSE . . . . . No. 4950

---

## The Commonwealth of Massachusetts

---

HOUSE OF REPRESENTATIVES, January 27, 2026.

The committee on Financial Services, to whom was referred the petition (accompanied by bill, House, No. 1240) of David Henry Argosky LeBoeuf and Lindsay N. Sabadosa relative to insulin access, reports recommending that the accompanying bill (House, No. 4950) ought to pass.

For the committee,

JAMES M. MURPHY.

## The Commonwealth of Massachusetts

**In the One Hundred and Ninety-Fourth General Court  
(2025-2026)**

## An Act relative to insulin access.

*Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:*

1 SECTION 1. Section 17G chapter 32A of the General Laws, as appearing in the 2022

2 Official Edition, is hereby amended by adding the following paragraph:-

3 The commission shall cap the total amount that an individual is required to pay for  
4 insulin at an amount not to exceed \$100 per a 30-day supply of insulin, regardless of the amou  
5 or type of insulin needed to fill the individual's prescription.

6 SECTION 2. Chapter 111N of the General Laws is hereby amended by adding the  
7 following section:-

8                   Section 9. (a) As used in this section, the following words shall, unless the context clearly  
9                   requires otherwise, have the following meanings:-

10 "Individuals who urgently need insulin", individuals who have less than a 7-day supply  
11 of insulin and are likely to ration insulin without assistance.

12           “Insulin patient assistance program”, assistance in the form of insulin free of charge for a  
13    specified duration provided by a manufacturer to an eligible individual, including, but not limited  
14    to: (i) directly to an eligible individual’s licensed practitioner for dispensing or (ii) to an eligible  
15    individual through a single-use card that can be used at a pharmacy when accompanied by a  
16    prescription.

17           (b) Every pharmaceutical or medical device manufacturing company, as defined in  
18    section 1, engaged in the production and distribution of insulin with a Medicaid drug rebate  
19    agreement pursuant to 42 USC 1396r-8 shall:

20           (1) Ensure that there exists an option as part of the pharmaceutical or medical device  
21    manufacturing company’s insulin patient assistance program offerings for individuals who  
22    urgently need insulin and are at risk of rationing to obtain an annual, one-time 30-day supply of  
23    insulin at no-cost; provided, that the individual: (i) has a prescription for insulin and (ii) provides  
24    written certification of financial need on a form to be provided by the department.

25           (2) Establish procedures to ensure that participation in the pharmaceutical or medical  
26    device manufacturing company’s insulin patient assistance program is available to individuals  
27    who satisfy manufacturer-defined eligibility criteria consistent with this paragraph. The  
28    pharmaceutical or medical device manufacturing company shall, at minimum:

29           (i) Make available on its website or a website specific to the insulin patient assistance  
30    program an application form for the pharmaceutical or medical device manufacturing company’s  
31    insulin patient assistance program;

32 (ii) Within 14 days of receipt of a completed application, issue a written determination to  
33 the applicant informing them of their eligibility or that more information is needed to determine  
34 eligibility;

35 (iii) Upon a determination that an applicant is eligible for the insulin patient assistance  
36 program, the pharmaceutical or medical device manufacturing company shall enroll the applicant  
37 in its insulin patient assistance program for 1 year, unless the applicant acquires government  
38 sponsored health insurance at any time during the year the applicant is enrolled in the program;  
39 and

40 (3) An individual shall be eligible for a pharmaceutical or medical device manufacturing  
41 company's insulin patient assistance program if:

42 (i) they are a United States citizen or legal resident;

43 (ii) they have a household income that is equal to or less than 400 per cent of the federal  
44 poverty guidelines;

45 (iii) they do not have private prescription drug coverage, including a health maintenance  
46 organization, also known as a HMO, or a preferred provider organization, also known as a PPO;  
47 and

48 (i) they are not eligible to receive prescription drug benefits through a federally funded  
49 program or through the Department of Veteran's Affairs; provided, however, that an individual  
50 who is enrolled in Medicare Part D may be eligible for a pharmaceutical or medical device  
51 manufacturing company's insulin patient assistance program if they meet all other eligibility

52 requirements and agree to any program terms and conditions set by the pharmaceutical or  
53 medical device manufacturing company.

54 (c) A pharmaceutical or medical device manufacturing company may establish a program  
55 to provide individuals who urgently need insulin through a single-use voucher that is redeemable  
56 at any retail pharmacy with a prescription.

57 (d) A pharmaceutical or medical device manufacturing company that fails to comply with  
58 this section shall be punished by a fine of \$100,000 per month of noncompliance.

59 SECTION 3. Section 10C of chapter 118E of the General Laws, as appearing in the 2022  
60 Official Edition, is hereby amended by adding the following paragraph:-

61 The division shall cap the total amount that an individual is required to pay for insulin at  
62 an amount not to exceed \$100 per a 30-day supply of insulin, regardless of the amount or type of  
63 insulin needed to fill the individual's prescription.

64 SECTION 4. Section 47N of chapter 175 of the General Laws, as so appearing, is hereby  
65 amended by adding the following paragraph:-

66 An insurer that provides coverage for insulin pursuant to this section shall cap the total  
67 amount that a policyholder is required to pay for insulin at an amount not to exceed \$100 per a  
68 30-day supply of insulin, regardless of the amount or type of insulin needed to fill the  
69 policyholder's prescription.

70 SECTION 5. Section 8P of chapter 176A of the General Laws, as appearing in the 2022  
71 Official Edition, is hereby amended by adding the following paragraph:-

72           A contract that provides benefits to individual subscribers or members for insulin  
73    pursuant to this section shall cap the total amount that an individual subscriber or member is  
74    required to pay for insulin at an amount not to exceed \$100 per a 30-day supply of insulin,  
75    regardless of the amount or type of insulin needed to fill the individual subscriber or member's  
76    prescription.

77           SECTION 6. Section 4S of chapter 176B of the General Laws, as so appearing, is hereby  
78    amended by adding the following paragraph:-

79           A subscription certificate that provides benefits to individual subscribers or members for  
80    insulin pursuant to this section shall cap the total amount that an individual subscriber or member  
81    is required to pay for insulin at an amount not to exceed \$100 per a 30-day supply of insulin,  
82    regardless of the amount or type of insulin needed to fill the individual subscriber or member's  
83    prescription.

84           SECTION 7. Section 4H of chapter 176G of the General Laws, as appearing in the 2022  
85    Official Edition, is hereby amended by adding the following paragraph:-

86           A contract that provides coverage for insulin pursuant to this section shall cap the total  
87    amount that an individual is required to pay for insulin at an amount not to exceed \$100 per a 30-  
88    day supply of insulin, regardless of the amount or type of insulin needed to fill the individual's  
89    prescription.